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Introduction: Benign prostate hyperplasia, pathophysiology contributes to bladder outlet obstruction 
due to functional obstruction caused by gland size enlargement resulting in the lower urinary tract 
symptoms (LUTS).
Objectives: To determine the correlation of the prostate volume with surgical outcomes and 
postoperative LUTS in patients with benign prostatic hyperplasia (BPH) undergoing transurethral 
resection of the prostate (TURP).
Patients and Methods: Patients with BPH who were refractory for medical treatment enrolled in 
the study. Patients divided into three groups with attention to their prostate volume conducted by 
transabdominal ultrasonography. To evaluate patients’ LUTS, the International Prostate Symptom 
Score (IPSS) questionnaire was filled for all patients preoperatively and during the first and third 
months follow up sessions. 
Results: In the current study, mean age of the patients was 66.92 ± 1.08 years. Of 111 patients, 
eight patients (7.2%) had prostate volume less than 30 cc, 59 patients (53.2%) had prostate volume 
between 30-60 cc, and 44 patients (39.6%) had prostate volume more than 60 cc. 
During first month postoperative, mean decrease in IPSS scores in patients with prostate volume less 
than 30 cc, prostate volume between 30–60 cc and prostate volume more than 30 cc were 27.72 ± 
3.53, 27.32 ± 3.37 and 27.45 ± 2.87, respectively. The ANOVA test showed no significant difference 
between the groups (P= 0.93). Mean decrease in IPSS score during third month postoperative, had 
no significant difference between the three groups, too (P=0.71). Symptoms alleviation observed in 
94.6% and 95.5% of the patients, during first and third months follow-up, respectively.
Conclusion: There was no correlation between the IPSS scores decrease and patients’ symptoms 
recovery and preoperative prostate volume in patients with BPH who underwent TRUP.
ABSTRACT
Implication for health policy/practice/research/medical education:
IPSS scores cannot predict  the patients’ symptoms recovery and preoperative prostate volume in patients following TRUP. 
Please cite this paper as: Lotfi B, Farazhi S, Mohammadi Fallah M, Alizadeh M, Valizadeh R, Mohammad Rahimi S. Effect of preoperative 
prostate volume on the improvement of lower urinary tract symptoms in patients with benign prostatic hyperplasia undergoing transurethral 
resection of prostate. J Nephropathol. 2020;9(2):e18. DOI: 10.34172/jnp.2020.18.
Introduction
Benign prostatic hyperplasia (BPH) is a common condition 
in elderly men, which occurs due to increase in number of 
the epithelial and stromal cells of the periurethral prostate. 
The incidence of the BPH arises from 10% during the 
4th decade to 88% in 8th and 100% in 9th decades of men 
life (1). The BPH pathophysiology contributes to bladder 
outlet obstruction due to functional obstruction caused 
by gland size enlargement (2). BPH is one of the leading 
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including urinary frequency and urinary urgency in men 
which varies in terms of severity in different patients (3). 
Although pharmacological therapies for BPH including 
5- α reductase inhibitor and α -1 receptor antagonists 
are the choice for patients who suffer LUTS, surgical 
interventions are needed to relieve symptoms in many 
patients who are refractory to medication or developed 
other complications such as hematuria, recurrent UTI and 
subsequent kidney diseases (2,4). Among various surgical 
approaches for BPH treatment, transurethral resection 
of the prostate (TURP) and transurethral incision of 
the prostate are two well-known surgical procedures. 
However, due to it is more efficacy in relieving patients’ 
symptoms including bladder outlet obstruction, TURP 
is now considered the gold standard method (2,5). 
Nevertheless, the surgical intervention has not been 
satisfactory to all patients, which has a dissatisfaction rate 
of 5%-35% among patients who underwent operations 
(6,7). Regarding the previous studies, the voiding 
dysfunctions such as frequency, urgency, dysuria and 
urinary incontinence are the most prevalent complaints 
of the patients after TURP (4, 8). Therefore, it seems 
that defining the underlying etiology of the voiding 
dysfunctions subsequent to TURP in BPH patients is 
important to take action for preventing poor surgical 
results. Some reports suggested that evaluation of the 
prostate size before surgical intervention in patients with 
BPH is important and may have correlation with surgical 
results in patients underwent TURP (9). Previously, 
some studies have discussed the prostate volume changes 
in trans-rectal ultrasonography (TRUS) and magnetic 
resonance imaging (MRI) before and after the TURP, but 
studies that have investigated the correlation between the 
prostate gland size and outcomes after the TURP, reported 
no significant correlation between the prostate size and 
surgery outcomes (10-12). In addition, it is proved that 
patients with similar prostate sizes do not develop the same 
LUTS (4). Therefore, international prostate symptom 
score (IPSS) has been introduced to rate the severity of 
the LUTS in patients with BPH which divides into three 
groups as follows: mild, moderate and severe. 
Objectives
With due attention to current controversy on the effect of 
the prostate size on TURP results, we aimed to investigate 
the correlation of the preoperative prostate size and LUTS 
severity after TURP in patients suffer BPH.
Patients and Methods 
Study design
From March 2014 to March 2015, a prospective study 
was carried in a single center in Urmia, West Azerbaijan 
of Iran. During this period, with due attention to pilot 
studies, 100 patients with LUTS secondary to BPH, 
refractory to medication and candidates for TURP, were 
enrolled in our study. Our exclusion criteria were bladder 
stone or diverticulitis, small bladder capacity, cystitis due 
to chemicals, tuberculosis or radiation, patients with 
urinary bladder tumors, urinary trauma, previous LUT 
operation, urethral stone retention, neurologic disorders, 
history of brain or spine trauma, complicated diabetes 
mellitus, cardiac or respiratory diseases and LUTS 
secondary to some drugs.
At first, all patients underwent transabdominal 
ultrasonography by a skilled sinologist, conducted using 
real-time scanning with a 3500 MHz transducer probe 
to determine the prostate volume. The prostate volume 
was estimated as the length × width × height × 0.52 and 
maximum dimensions of the whole prostate were used for 
total prostate volume estimation. Subsequently, patients 
divided into three groups with due attention to their 
prostate volume including patients with <30 cc prostate 
volume, patients with prostate volume of 30–60 cc, and 
patients with ≥60 cc prostate volume. To assess the LUTS 
severity, the IPSS questionnaire was completed for all 
patients, preoperatively. 
During TURP, subsequent to spinal anesthesia by 3F 
epidural catheter, patients settled in lithotomy position 
and single urologist (supervisor) performed transurethral 
resection of the prostate using 24F shit resectoscope. 
In order to bladder washing, the saline infused into the 
bladder at speed of 50 mL/min through the 24F urethral 
catheter. Right after resection completion and removing 
the prostate chips, resectoscope removed. All patients 
were discharged during 24 hours postoperatively and oral 
antibiotics were given for 3 days to prevent UTI. However, 
Foley catheters were removed 3 days after TURP and 
voiding trial performed at this time.
Two weeks postoperatively, IPSS score, LUTS severity 
and need for medical treatment to reveal LUTS were 
evaluated. In case of patients’ satisfaction with symptoms, 
next follow up session would take place at first and third 
months postoperatively, to calculate the IPSS score. 
However, in case of dissatisfaction, follow up sessions 
would take place at shorter intervals. During session’s 
interval, any drug consumption for one week was recorded.
Ethical considerations
This study was approved by the Ethics Committee of 
the Urmia University of Medical Sciences (IR.USMU.
REC.1393.233). All procedures performed in studies 
involving human participants in accordance with the 
ethical standards of the institutional and national research 
committee and with the 1964 Helsinki declaration and its 
later amendments. All participants provided written and 
informed consent. 
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Statistical analysis
All data were analyzed using SPSS version 18. Software 
(SPSS Inc., Chicago, IL). To express the quantitative 
values, we used mean ± SD. Comparison between 
groups was performed using student t test and χ2 test for 
paired data and results with P < 0.05 were considered as 
statistically significant.
Results
In the current study, patients with symptomatic or 
complicated BPH and refractory to medical treatment 
who underwent TURP, participated. Of 143 patients, 23 
patients were excluded and 120 patients were eligible to 
be enrolled in our study, however, out of 120 patients, 9 
patients did not complete their follow up sessions and 111 
patients enrolled in analysis. Mean age of the patients was 
66.92 ± 1.08 years, ranging from 44 to 100 years old. Of 
111 patients, 8 patients (7.2%) had the prostate volume 
less than 30cc, 59 patients (53.2%) had the prostate 
volume between 30 cc to 60 cc, and 44 patients (39.6%) 
had the prostate volume more than 60 cc.
LUTS recovery was considered as IPSS score ranging 
diminish to mild. During the first postoperative month, 
recovery observed in 105 patients (94.6%) and in 106 
patients (95.5%) during the third month. IPSS scores 
during preoperative, first month postoperative and third 
month postoperative in patients with the total prostate 
volume less than 30cc were as follows; 32.62 ± 2.19, 4.87 
± 2.41 and 3.62 ± 3.20. However, in patients with the 
total prostate size between 30 cc to 60 cc, IPSS scores in 
the mentioned periods were 31.32 ± 2.89, 4 ± 1.88 and 
3.25 ± 2.06. Finally, 31.04 ± 2.63, 3.59 ± 1.22 and 2.68 ± 
1.47 were the preoperative, first month postoperative and 
third month postoperative IPSS scores in patients with 
the total prostate volume more than 60 cc, respectively 
(Table 1). 
Using ANOVA test, the mean ± SD of the IPSS score 
changes during first month postoperative compared in 
three group, which were 27.75 ± 3.53 in patients with the 
prostate volume less than 30cc, 27.32 ± 3.37 in patients 
with the prostate volume of 30cc to 60cc and 27.45 ± 
2.87 in patients with the prostate volume more than 60cc, 
since no statistically significant difference was observed 
between the prostate volume and IPSS score decrease in 
patients (P = 0.93).
During third month postoperative, the mean ± SD 
of IPSS score decreasing, in patients with the prostate 
volume less than 30 cc, patients with the prostate volume 
between 30–60 cc and patients with the prostate size more 
than 60 cc were 29±4.20, 28.06±3.31 and 28.36±3.23, 
respectively. The ANOVA test showed no significant 
difference between the prostate volume and IPSS score 
decrease during the third month postoperative (P = 0.71). 
During postoperative follow up period, 18 patients 
received medical treatment due to LUTS, whereas three 
patients (16.7%) had the prostate volume less than 30cc, 
10 patients (55.6%) had the prostate volume more than 
60 cc. Chi-square test proved no significant relationship 
between the prostate volume and postoperative medical 
treatment in patients (P > 0.05) (Table 2).
Discussion
In the current study, the results showed that the 
preoperative total prostate volume in patients of the three 
groups had no significant effect on the postoperative IPSS 
score decrease or patients’ symptom recovery. In addition, 
the preoperative prostate size is not a significant predictor 
of the postoperative need for medical treatment in order 
to decrease LUTS.
BPH is a pathologic increase in glandular and stromal 
tissues of the prostate that causes different complications 
including bladder outlet obstruction and LUTS in aging 
Table 1. Preoperative, first and third month postoperative IPSS score mean ± SD in patients of the three groups
Prostate volume
IPSS score
Preoperative First month postoperative Third month postoperative
≤30 cc 32.62 ± 2.19 4.87 ± 2.41 3.62 ± 3.20
30–60 cc 32.32 ± 2.89 4 ± 1.88 3.25 ± 2.06
≥ 60 cc 31.04 ± 2.63 3.59 ± 1.22 2.68 ± 1.47
Table 2. Comparison of IPSS decrease mean ± SD between three groups during first and third months follow up
Prostate 
volume
IPSS decrease mean ± SD ANOVA test
First month postoperative Third month postoperative
First month postoperative Third month postoperative
Group P value Group P value
≤ 30 cc 27.75 ± 3.53 29 ± 4.20 30 – 60 CC 0.72 30 – 60 CC 0.44≥ 60cc 0.81 ≥ 60cc 0.61
30-60 cc 27.32 ± 3.37 28.06 ± 3.31 ≤ 30cc 0.72 ≤ 30cc 0.44≥ 60cc 0.83 ≥ 60cc 0.64
≥ 60 cc 27.45 ± 2.87 28.36 ± 3.23 - -
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men (4,13,14). Although two hypotheses have been 
described to have a role in BPH including epithelial cell 
proliferation and defect in cell apoptosis, the main etiology 
of the BPH is still unknown. LUTS subdivides to voiding 
symptoms such as frequency and urgency and storage 
symptoms (2). Despite focus of the medical and surgical 
treatments on alleviation of the voiding symptoms, Irwin 
et al believe that storage symptoms are more prevalent 
than voiding symptoms that effect patient’s quality of life 
significantly (15). Since there is an incompatibility between 
the prostate volume and LTUS, in order to categorize the 
LTUS in BPH patients, urologists IPSS which subdivides 
patients’ symptoms to three subgroups as follows; mild, 
moderate and severe. According to previous studies, 
the BPH prevalence increases from 50-60% during the 
seventh decade of life to approximately 90% during 
eighth decades (16). The aim of the BPH treatment is to 
decrease IPSS score, eliminating hematuria secondary to 
BPH, improving bladder emptying, diminishing post-
void residual and preventing acute urinary retention (17). 
Medical treatment is the treatment of the choice in BPH 
patients, but in the future many patients become refractory 
to medical therapy and need surgical interventions. 
Although several minimally invasive procedures have been 
described for BPH treatment, TURP is still considered as 
gold standard for BPH treatment (18). However, some 
studies reported dissatisfactory subsequent to TURP in 
approximately one-third of the patients, due to persistent 
voiding dysfunction (6,7). Some studies suggest that 
the prevalence of urgency and frequency is 20%-35% 
postoperatively, however urodynamic obstruction develops 
in 4%-37% of the patients after TURP (4,8,19,20). 
Nevertheless, preoperative symptoms are not a reliable 
predictor of the postoperative outcomes.
Previous studies have noted that mean rate of the 
symptoms recovery after TURP is 88%, ranging from 
70% to 96%, so that Jang et al reported that among 
interventional treatments for BPH, TURP is increasing 
since 2000 (21). Moreover, Bozdar et al used IPSS to 
evaluate LTUS improvement in BPH patients subsequent 
to TURP. During a 12-month follow up, of 70 patients, 
IPSS scores reduce to mild degree in 88.5% of the patients 
after TURP (22). In the current study, results showed 
symptoms improvement in 94.6% of the patients during 
the first month postoperative and in 95.9% of the patients 
during the third month postoperative, which proves the 
TURP efficacy in our study. 
Since, postoperative LTUS in patients who underwent 
TURP has a significant impact on the patients’ quality 
of life, it is essential to investigate its underlying 
pathophysiology. In addition, considering the underlying 
pathophysiology will help to predict the probable poor 
surgical results in patients. Hakenberg et al demonstrated 
that initial improvement subsequent to TURP does not 
depend on the ratio of the complete resection of the prostate 
tissue (23). In addition, they believed that more amount 
of the resected tissue leads to significant improvement of 
the LUTS (23). In another study by Chen et al, the results 
showed that less prostate tissue residue after TURP leads 
to better surgical results (9). However, in the current study 
postoperative symptoms improvement after TURP in 
patients with smaller prostate volume had no significant 
difference in comparison to other groups.
In our study, some patients still suffer from LUTS after 
TURP, since the IPSS score decrease, subsequent to TURP 
varies in BPH patients. In a study, Kang et al evaluated 
efficacy of the TURP with due attention to postoperative 
changes in storage symptoms and the prostate volume of the 
patients (2). The results showed that TURP is an efficient 
procedure for BPH treatment, however, no significant 
difference in storage symptoms recovery between patients 
with the prostate volume less than 30 cc and patients with 
the prostate volume more than 30 cc was observed. In 
the present study, patients were divided to three groups 
with due attention to their prostate volume, and IPSS 
scores recorded pre and postoperatively. In comparison to 
previous studies, our results showed that all groups had 
decrease in postoperative IPSS scores in comparison to 
preoperative scores, especially in patients with prostate 
volume lass than 30cc. In other word, even in patients 
with low-prostate volume appropriate patient selection 
can lead to better surgical results. Moreover, there were 
no significant differences between IPSS scoring decrease 
between three groups during the follow up period. 
Despite previous studies, our results showed that the 
prostate volume had no significant correlation with the 
decrease of IPSS scores in follow up period, and it was not 
a reliable predictor of the postoperative LUTS, which can 
be related to the selection of patient in the current study.
Recently, Lin et al carried out a retrospective study to 
investigate the correlation between the resected prostate 
adenoma weight and postoperative need for medical 
treatment. Their results showed that smaller prostate 
volume can significantly predict medical treatment need 
after TURP (24). In our study, we observed no significant 
correlation between the preoperative prostate volume with 
postoperative medical treatment.
Our study was of some limitations. First, some patients 
received anticholinergic drugs for maximum four weeks 
due to their postoperative voiding symptoms, which 
could alter the IPSS score of the patients during first 
month follow up. However, since similar results observed 
during third month follow up, its alteration impact may 
be diminished. Second, multi-centric study can provide 
much more reliable results. 
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Conclusion
The preoperative prostate volume had no correlation with 
IPSS score decrease and patients’ symptoms recovery. 
Therefore, urologists can candidate patients with severe 
LUTS to undergo TURP without taking prostate 
volume into consideration since prostate volume has no 
correlation with surgical outcomes and postoperative 
medical treatment.
Study limitations
Given that this study was prospective, however the 
sample size was relatively small due to the nature of the 
disease. Also, this study was single center and cannot be 
generalized enough. 
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